In April 2014, the US Food and Drug Administration (FDA) approved ceritinib (Zykadia) for treatment of ALK-positive metastatic NSCLC in patients who have previously received or are intolerant to crizotinib (FDA, 2014). Here, ALK is linked to non-small cell lung carcinoma.